3 studies found for:    8710059 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Safety Study of TPI-287 to Treat CBS and PSP
Conditions: Primary Four Repeat Tauopathies (4RT);   Corticobasal Syndrome (CBS);   Progressive Supranuclear Palsy (PSP)
Interventions: Drug: TPI 287  2 mg/m2;   Drug: TPI-287 20 mg/m2;   Drug: Placebo;   Drug: TPI-287 6.3 mg/m2
2 Recruiting Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Conditions: Alzheimer's Disease (AD);   Parkinson's Disease (PD);   Chronic Traumatic Encephalopathy (CTE);   Progressive Supranuclear Palsy (PSP);   Frontal Temporal Dementia (FTD);   Pick's Disease;   Tauopathies
Intervention: Drug: [18F]T807 ([18F]MNI-777)
3 Active, not recruiting Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
Conditions: Predicted Tauopathies, Including:;   Progressive Supranuclear Palsy;   Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;   Corticobasal Degeneration Syndrome;   Progressive Nonfluent Aphasia
Interventions: Drug: davunetide (AL-108, NAP);   Drug: Placebo nasal spray

Indicates status has not been verified in more than two years